Literature DB >> 33392097

Modeling the Leukemia Microenviroment In Vitro.

Cristina Scielzo1, Paolo Ghia2,3,4.   

Abstract

Over the last decade, the active role of the microenvironment in the pathogenesis, development and drug resistance of B cell malignancies has been clearly established. It is known that the tissue microenvironment promotes proliferation and drug resistance of leukemic cells suggesting that successful treatments of B cell malignancies must target the leukemic cells within these compartments. However, the cross-talk occurring between cancer cells and the tissue microenvironment still needs to be fully elucidated. In solid tumors, this lack of knowledge has led to the development of new and more complex in vitro models able to successfully mimic the in vivo settings, while only a few simplified models are available for haematological cancers, commonly relying only on the co-culture with stabilized stromal cells and/or the addition of limited cocktails of cytokines. Here, we will review the known cellular and molecular interactions occurring between monoclonal B lymphocytes and their tissue microenvironment and the current literature describing innovative in vitro models developed in particular to study chronic lymphocytic leukemia (CLL). We will also elaborate on the possibility to further improve such systems based on the current knowledge of the key molecules/signals present in the microenvironment. In particular, we think that future models should be developed as 3D culture systems with a higher level of cellular and molecular complexity, to replicate microenvironmental-induced signaling. We believe that innovative 3D-models may therefore improve the knowledge on pathogenic mechanisms leading to the dissemination and homing of leukemia cells and consequently the identification of therapeutic targets.
Copyright © 2020 Scielzo and Ghia.

Entities:  

Keywords:  3D models (three dimensional); B cell malignancies; chronic lymphocytic leukemia (CLL); in vitro; microenvironment

Year:  2020        PMID: 33392097      PMCID: PMC7773937          DOI: 10.3389/fonc.2020.607608

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  7 in total

Review 1.  In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Authors:  Eva Hoferkova; Sona Kadakova; Marek Mraz
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

2.  Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.

Authors:  David E Spaner; Yuxuan Luo; Guizhei Wang; Jennifer Gallagher; Hubert Tsui; Yonghong Shi
Journal:  Cancer Med       Date:  2021-11-17       Impact factor: 4.452

3.  Editorial: New Insights Into the Complexity of Tumor Immunology in B-Cell Malignancies: Disease Biology and Signaling.

Authors:  Jérôme Paggetti; Martina Seiffert; Etienne Moussay
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

Review 4.  O-GlcNAcylation in Chronic Lymphocytic Leukemia and Other Blood Cancers.

Authors:  David E Spaner
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

5.  Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system.

Authors:  Daniela Belloni; Marina Ferrarini; Elisabetta Ferrero; Virginia Guzzeloni; Federica Barbaglio; Paolo Ghia; Cristina Scielzo
Journal:  STAR Protoc       Date:  2022-08-10

Review 6.  Protein Phosphorylation and Redox Status: An as Yet Elusive Dyad in Chronic Lymphocytic Leukemia.

Authors:  Mario Angelo Pagano; Federica Frezzato; Andrea Visentin; Livio Trentin; Anna Maria Brunati
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

7.  Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia.

Authors:  Xiaoya Yun; Xiang Sun; Xinting Hu; Huimin Zhang; Zixun Yin; Xin Zhang; Ming Liu; Ya Zhang; Xin Wang
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.